Akoya Biosciences Balance Sheet Health
Financial Health criteria checks 2/6
Akoya Biosciences has a total shareholder equity of $13.6M and total debt of $75.9M, which brings its debt-to-equity ratio to 556.8%. Its total assets and total liabilities are $130.0M and $116.3M respectively.
Key information
556.8%
Debt to equity ratio
US$75.90m
Debt
Interest coverage ratio | n/a |
Cash | US$35.90m |
Equity | US$13.63m |
Total liabilities | US$116.34m |
Total assets | US$129.97m |
Recent financial health updates
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?
Nov 12Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Jun 24Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28Recent updates
Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower
Dec 14Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)
Nov 19Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?
Nov 12Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company
Oct 08Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target
Aug 09Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost
Jun 27Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Jun 24We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now
May 29Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)
May 10Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Akoya Biosciences Seeks Growth Despite Higher Operating Losses
May 30Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Financial Position Analysis
Short Term Liabilities: AKYA's short term assets ($76.9M) exceed its short term liabilities ($28.0M).
Long Term Liabilities: AKYA's short term assets ($76.9M) do not cover its long term liabilities ($88.3M).
Debt to Equity History and Analysis
Debt Level: AKYA's net debt to equity ratio (293.4%) is considered high.
Reducing Debt: Insufficient data to determine if AKYA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKYA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AKYA has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 23.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/11 22:19 |
End of Day Share Price | 2025/03/11 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akoya Biosciences, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mark Massaro | BTIG |
Kyle Mikson | Canaccord Genuity |
Timothy Chiang | Capital One Securities, Inc. |